Eisai R&d Management Co., Ltd.

Chiba University

Toshifumi Hirayama

Toshio Imai

Eiji Inoue

Toshinori Nakayama

Kenzo Muramoto

Yuichi Ono

Yoshimasa Sakamoto

Shunsuke Ito

Akio Yamada

Koji Hayashizaki

Aki Nakatani

Daisuke Tokita

Ryota Taguchi

Jungo Kakuta

Motoko Kimura

Ryu Gejima

The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.

Anti-MYL9 antibody

It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.

Anti-EphA4 antibody

Growing community of inventors

Kobe, Japan

Toshifumi Hirayama